{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:19:10Z","timestamp":1762867150533,"version":"3.38.0"},"reference-count":15,"publisher":"JLE","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.nephro.2017.01.016","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T06:15:57Z","timestamp":1496297757000},"page":"S109-S113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"S1","title":["Thrombotic microangiopathies and antineoplastic agents"],"prefix":"10.1684","volume":"13","author":[{"given":"Steven","family":"Grang\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2017.01.016_bib0080","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00062752-200109000-00004","article-title":"Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"8","author":"Medina","year":"2001","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.nephro.2017.01.016_bib0085","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","article-title":"Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry","volume":"7","author":"Lesesne","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2017.01.016_bib0090","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.016_bib0095","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","article-title":"Gemcitabine-associated thrombotic thrombocytopenic purpura","volume":"8","author":"Zupancic","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nephro.2017.01.016_bib0100","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Al Ustwani","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.nephro.2017.01.016_bib0105","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bjh.12686","article-title":"Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy","volume":"164","author":"Starck","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nephro.2017.01.016_bib0110","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.revmed.2015.12.027","article-title":"[Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: a case report]","volume":"37","author":"Rogier","year":"2016","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.nephro.2017.01.016_bib0115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nephro.2017.01.016_bib0120","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.01.016_bib0125","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ndt\/gft465","article-title":"All anti-vascular endothelial growth factor drugs can induce \u201cpre-eclampsia-like syndrome\u201d: a RARe study","volume":"29","author":"Vigneau","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.016_bib0130","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.01.016_bib0135","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","author":"Yui","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.nephro.2017.01.016_bib0140","first-page":"254","article-title":"Oxaliplatin-induced acute renal failure presenting clinically as thrombotic microangiopathy: think of acute tubular necrosis","volume":"2","author":"Phan","year":"2009","journal-title":"NDT Plus"},{"key":"10.1016\/j.nephro.2017.01.016_bib0145","first-page":"29","article-title":"A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib","volume":"2","author":"Martino","year":"2013","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.nephro.2017.01.016_bib0150","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1634\/theoncologist.2009-0067","article-title":"Cancer awareness in atypical thrombotic microangiopathies","volume":"14","author":"Oberic","year":"2009","journal-title":"Oncologist"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517300408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517300408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2017.01.016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:42:14Z","timestamp":1741192934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725517300408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":15,"alternative-id":["S1769725517300408"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2017.01.016","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic microangiopathies and antineoplastic agents","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2017.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}